| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Kiniksa Pharmaceuticals International, Plc's insiders have reduced their positions by a net 4,600 shares worth roughly $369K.
Classified under Pharmaceuticals (Health Care sector), KNSA's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.74M | - | - | |
| CEO | 92.3K | $7.32M | - | |
| Other | 69.9K | $5.54M | - | |
| Other | 29.1K | $2.33M | - | |
| Other | 23.1K | $1.13M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6, 2026 | Moat Ross | Chief Operating Officer | Sale+OE | 2,367 | $48.58 | $114,988.86 | -16.4% | +26.7% | - | |
| Mar 9, 2026 | Ragosa Mark | Chief Financial Officer | Sale+OE | 36,722 | $45.92 | $1,686,157.82 | -75.2% | +4.8% | - | |
| Mar 2, 2026 | Paolini John F.51 | Chief Medical Officer | Sale+OE | 40,000 | $44.82 | $1,792,939.72 | -39.5% | +5.2% | - | |
| Feb 12, 2026 | Quart Barry D | Director | Sale+OE | 2,800 | $45.00 | $126,000.00 | -18.2% | +32.2% | - | |
| Feb 9, 2026 | Ragosa Mark | Chief Financial Officer | Sale+OE | 17,845 | $43.28 | $772,254.22 | -59.6% | +31.6% | - | |
| Feb 4, 2026 | Quart Barry D | Director | Sale+OE | 15,960 | $45.22 | $721,634.60 | -56.0% | +30.4% | - | |
| Jan 8, 2026 | Ragosa Mark | Chief Financial Officer | Sell | 12,000 | $41.89 | $502,680.00 | -38.6% | +12.7% | - | |
| Dec 15, 2025 | Tessari Eben | Chief Operating Officer | Sale+OE | 12,048 | $41.56 | $500,714.88 | -42.0% | +11.9% | - | |
| Dec 15, 2025 | Quart Barry D | Director | Sale+OE | 20,129 | $41.51 | $835,554.79 | -61.6% | +11.9% | - | |
| Dec 8, 2025 | Ragosa Mark | Chief Financial Officer | Sale+OE | 42,841 | $41.49 | $1,777,473.09 | -58.0% | +12.6% | - |